Search

Your search keyword '"Findling, Robert L."' showing total 1,379 results
Start Over Author "Findling, Robert L." Language english
1,379 results on '"Findling, Robert L."'

3. International consensus on sleep problems in pediatric palliative care: Paving the way

Author

Li, Albert, Wolfson, Amy R., Marinetto, Anna, Santini, Anna, Zanin, Anna, Kuhn, Brett R., Angelhoff, Charlotte, Santos, Cristiane Fumo dos, Goh, Daniel Y.T., Verrillo, Elisabetta, Zhou, Eric S., Ferreira, Esther Angélica Luiz, Bergstraesser, Eva, Pizza, Fabio, Nilsson, Frans, Plazzi, Giuseppe, Wang, Guanghai, Traslaviña, Guillermo Andrey Ariza, Moreira, Gustavo Antonio, Siden, Hal, Hauch, Holger, Huijer, Huda Abu-Saad, Catalano, Igor, Narang, Indra, Avagnina, Irene, Lopez, Jaime Gutierrez Del Alamo, Wille, Joakim, Mindell, Jodi, Bogetz, Jori, Downing, Julia, Hauer, Julie, Streuli, Jürg, Baker, Justin, Spruyt, Karen, Chan, Kate Ching Ching, Soster, Leticia Azevedo, Oliveira, Lia, Ragsdale, Lindsay, Nobili, Lino, Matlen, Lisa, Nosetti, Luana, De Zen, Lucia, Strambi, Luigi Ferini, Stenmarker, Margaretha, Lopes, Maria Cecilia, Blankenburg, Markus, Rios, Marta, Bernadá, Mercedes, Farquhar, Michael, Frühwald, Michael, Gradisar, Michael, Simakajornboon, Narong, Lazzarin, Pierina, Chong, Poh-Heng, Ferri, Raffaele, Martino-Alba, Ricardo, Findling, Robert L., Ferreira, Rosário, Bin-Hasan, Saadoun, Kudchadkar, Sapna R., Mercadante, Sebastiano, Amarri, Sergio, Keenan, Sharon, Noce, Silvia, de Oliveira Iglesias, Simone Brasil, Fagondes, Simone, Suh, Sooyeon, Sheldon, Stephen H., Sejersen, Thomas, Ceranoglu, Tolga Atilla, Crabtree, Valerie, Castronovo, Vincenza, Mercante, Anna, Owens, Judith, Bruni, Oliviero, Nunes, Magda L., Gringras, Paul, Li, Shirley Xin, Papa, Simonetta, Kreicbergs, Ulrika, Wolfe, Joanne, Zernikow, Boris, Lacerda, Ana, and Benini, Franca

Published
2024
Full Text
View/download PDF

6. Research Agenda in Childhood Impairing Emotional Outbursts: A Report of the AACAP Presidential Taskforce on Emotional Dysregulation

Author

Althoff, Robert R., Singh, Manpreet K., Stringaris, Argyris, Constantino, John N., Amaya-Jackson, Lisa, Benton, Tami D., Bellonci, Christopher, Bostic, Jeff Q., Chua, Jaclyn Datar, Findling, Robert L., Galanter, Cathryn A., Gerson, Ruth S., McClellan, Jon M., Sorter, Michael T., Waxmonsky, James G., and Carlson, Gabrielle A.

Published
2024
Full Text
View/download PDF

21. Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver's Quality of Life

Author

Schroder, Carmen M., Malow, Beth A., Maras, Athanasios, Melmed, Raun D., Findling, Robert L., Breddy, John, Nir, Tali, Shahmoon, Shiri, Zisapel, Nava, and Gringras, Paul

Abstract

A randomized, 13-weeks, placebo-controlled double-blind study in 125 subjects aged 2-17.5 years with Autism Spectrum Disorder or Smith-Magenis syndrome and insomnia demonstrated efficacy and safety of easily-swallowed prolonged-release melatonin mini-tablets (PedPRM; 2-5 mg) in improving sleep duration and onset. Treatment effects on child behavior and caregiver's quality of life were evaluated. PedPRM treatment resulted in significant improvement in externalizing but not internalizing behavior (Strengths and Difficulties questionnaire; SDQ) compared to placebo (p = 0.021) with clinically-relevant improvements in 53.7% of PedPRM-treated versus 27.6% of placebo-treated subjects (p = 0.008). Caregivers' quality of life also improved with PedPRM versus placebo (p = 0.010) and correlated with the change in total SDQ (p = 0.0005). PedPRM alleviates insomnia-related difficulties, particularly externalizing behavior in the children, subsequently improving caregivers' quality of life.

Published
2019
Full Text
View/download PDF

30. A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders

Author

Peterson, Bradley S., West, Amy E., Weisz, John R., Mack, Wendy J., Kipke, Michele D., Findling, Robert L., Mittman, Brian S., Bansal, Ravi, Piantadosi, Steven, Takata, Glenn, Koebnick, Corinna, Ashen, Ceth, Snowdy, Christopher, Poulsen, Marie, Arora, Bhavana Kumar, Allem, Courtney M., Perez, Marisa, Marcy, Stephanie N., Hudson, Bradley O., Chan, Stephanie H., and Weersing, Robin

Published
2021
Full Text
View/download PDF

32. Clinical, cortical thickness and neural activity predictors of future affective lability in youth at risk for bipolar disorder: initial discovery and independent sample replication

Author

Bertocci, Michele A., Hanford, Lindsay, Manelis, Anna, Iyengar, Satish, Youngstrom, Eric A., Gill, Mary Kay, Monk, Kelly, Versace, Amelia, Bonar, Lisa, Bebko, Genna, Ladouceur, Cecile D., Perlman, Susan B, Diler, Rasim, Horwitz, Sarah M., Arnold, L. Eugene, Hafeman, Danella, Travis, Michael J., Kowatch, Robert, Holland, Scott K., Fristad, Mary. A., Findling, Robert L., Birmaher, Boris, and Phillips, Mary L.

Published
2019
Full Text
View/download PDF

36. Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Author

Williams Buckley, Ashura, Hirtz, Deborah, Oskoui, Maryam, Armstrong, Melissa J., Batra, Anshu, Bridgemohan, Carolyn, Coury, Daniel, Dawson, Geraldine, Donley, Diane, Findling, Robert L., Gaughan, Thomas, Gloss, David, Gronseth, Gary, Kessler, Riley, Merillat, Shannon, Michelson, David, Owens, Judith, Pringsheim, Tamara, Sikich, Linmarie, Stahmer, Aubyn, Thurm, Audrey, Tuchman, Roberto, Warren, Zachary, Wetherby, Amy, Wiznitzer, Max, and Ashwal, Stephen

Published
2020
Full Text
View/download PDF

37. Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver's Quality of Life

Author

Schroder, Carmen M., Malow, Beth A., Maras, Athanasios, Melmed, Raun D., Findling, Robert L., Breddy, John, and Nir, Tali

Subjects
Insomnia -- Care and treatment, Melatonin -- Usage -- Safety and security measures, Children -- Behavior, Caregivers -- Health aspects, Quality of life -- Analysis, Health
Abstract

A randomized, 13-weeks, placebo-controlled double-blind study in 125 subjects aged 2-17.5 years with Autism Spectrum Disorder or Smith-Magenis syndrome and insomnia demonstrated efficacy and safety of easily-swallowed prolonged-release melatonin mini-tablets (PedPRM; 2-5 mg) in improving sleep duration and onset. Treatment effects on child behavior and caregiver's quality of life were evaluated. PedPRM treatment resulted in significant improvement in externalizing but not internalizing behavior (Strengths and Difficulties questionnaire; SDQ) compared to placebo (p = 0.021) with clinically-relevant improvements in 53.7% of PedPRM-treated versus 27.6% of placebo-treated subjects (p = 0.008). Caregivers' quality of life also improved with PedPRM versus placebo (p = 0.010) and correlated with the change in total SDQ (p = 0.0005). PedPRM alleviates insomnia-related difficulties, particularly externalizing behavior in the children, subsequently improving caregivers' quality of life., Author(s): Carmen M. Schroder [sup.1] [sup.2] , Beth A. Malow [sup.3] , Athanasios Maras [sup.4] , Raun D. Melmed [sup.5] , Robert L. Findling [sup.6] , John Breddy [sup.7] , [...]

Published
2019
Full Text
View/download PDF

43. Longitudinal Relationships Among Activity in Attention Redirection Neural Circuitry and Symptom Severity in Youth

Author

Bertocci, Michele A., Bebko, Genna, Dwojak, Amanda, Iyengar, Satish, Ladouceur, Cecile D., Fournier, Jay C., Versace, Amelia, Perlman, Susan B., Almeida, Jorge R.C., Travis, Michael J., Gill, Mary Kay, Bonar, Lisa, Schirda, Claudiu, Diwadkar, Vaibhav A., Sunshine, Jeffrey L., Holland, Scott K., Kowatch, Robert A., Birmaher, Boris, Axelson, David, Horwitz, Sarah M., Frazier, Thomas, Arnold, L. Eugene, Fristad, Mary A., Youngstrom, Eric A., Findling, Robert L., and Phillips, Mary L.

Published
2017
Full Text
View/download PDF

45. Amygdala-prefrontal cortical functional connectivity during implicit emotion processing differentiates youth with bipolar spectrum from youth with externalizing disorders

Author

Hafeman, Danella, Bebko, Genna, Bertocci, Michele A., Fournier, Jay C., Chase, Henry W., Bonar, Lisa, Perlman, Susan B., Travis, Michael, Gill, Mary Kay, Diwadkar, Vaibhav A., Sunshine, Jeffrey L., Holland, Scott K., Kowatch, Robert A., Birmaher, Boris, Axelson, David, Horwitz, Sarah M., Arnold, L. Eugene, Fristad, Mary A., Frazier, Thomas W., Youngstrom, Eric A., Findling, Robert L., and Phillips, Mary L.

Published
2017
Full Text
View/download PDF

46. Adequacy of Children's Psychopharmacology Services: Variations by Race and Clinical Characteristics.

Author

Young, Andrea S., Findling, Robert L., Riehm, Kira E., Seegan, Paige, Crum, Rosa M., Mojtabai, Ramin, Chiappini, Erika A., Youngstrom, Eric A., Fristad, Mary A., Arnold, L. Eugene, Birmaher, Boris, and Horwitz, Sarah M.

Subjects
PSYCHOPHARMACOLOGY, MEDICAL care use, MENTAL illness, PEDIATRIC clinics, SECONDARY education, BLACK children, PSYCHOTHERAPISTS
Abstract

An expert consensus approach was used to determine the adequacy of children's psychopharmacology and to examine whether adequacy varied by demographic or clinical characteristics. Data were from the baseline interview of 601 children, ages 6–12 years, who had visited one of nine outpatient mental health clinics and participated in the Longitudinal Assessment of Manic Symptoms study. Children and parents were interviewed with the Kiddie Schedule for Affective Disorders and Schizophrenia and the Service Assessment for Children and Adolescents to assess the child's psychiatric symptoms and lifetime mental health services use, respectively. An expert consensus approach informed by published treatment guidelines was used to determine the adequacy of children's psychotropic medication treatment. Black children (compared with White children; OR=1.84, 95% CI=1.53–2.23) and those with anxiety disorders (vs. no anxiety disorder; OR=1.55, 95% CI=1.08–2.20) were more likely to receive inadequate pharmacotherapy; those whose caregivers had a bachelor's degree or more education (vs. those who had a high school education, general equivalency diploma, or less than high school education; OR=0.74, 95% CI=0.61–0.89) were less likely to receive inadequate pharmacotherapy. The consensus rater approach permitted use of published treatment efficacy data and patient characteristics (e.g., age, diagnoses, history of recent hospitalizations, and psychotherapy) to assess adequacy of pharmacotherapy. These results replicate findings of racial disparities reported in previous research using traditional methods to determine treatment adequacy (e.g., with a minimum number of treatment sessions) and highlight the continued need for research on racial disparities and strategies to improve access to high-quality care. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Comparing self‐reported quality of life in youth with bipolar versus other disorders.

Author

McGinty, Kayla R., Janos, Jessica, Seay, Julia, Youngstrom, Jennifer K., Findling, Robert L., Youngstrom, Eric A., and Freeman, Andrew J.

Subjects
BEHAVIOR disorders, CHILD Behavior Checklist, AFFECTIVE disorders, MENTAL illness, QUALITY of life, HYPOMANIA
Abstract

Objectives: This study benchmarks quality of life (QoL) of youth with bipolar disorder (BD) against healthy youth, youth with chronic medical conditions, and youth with other psychiatric disorders. The relative impacts of depressive, (hypo)manic, mixed, and externalizing symptoms on QoL are tested for youth with BD. Method: In total, 657 youth completed the Schedule for Affective Disorders and Schizophrenia for Children (KSADS), the KSADS depression and mania scales, the Parent General Behavior Inventory (PGBI), and the Child Behavior Checklist (CBCL). Youth‐reported QoL was determined by the Revised Children Quality of Life Questionnaire (KINDL) and was compared to healthy youth, youth with chronic medical conditions, and youth with other psychiatric disorders. Results: Youth with BD reported poorer QoL overall and on most subscales compared to healthy youth, youth with chronic medical conditions, youth with behavior disorders, and youth with other non‐behavior/non‐mood disorders. QoL in youth with BD did not differ significantly from QoL in youth with unipolar depression. Parent‐report and interview‐rated depressive symptoms were associated with decreases in Total QoL and all QoL subscales except Family. Externalizing symptoms were associated with decreases in Family QoL and increases in Friend QoL, and (hypo)manic symptoms were associated with increases in Emotional Well‐Being QoL. Conclusions: Depressive symptoms may drive the decline in QoL causing youth with BD to rate their QoL worse than healthy youth, youth with chronic medical conditions, and youth with behavior disorders, but not worse than youth with unipolar depression. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Reorienting Latent Variable Modeling for Supervised Learning.

Author

Jo, Booil, Hastie, Trevor J., Li, Zetan, Youngstrom, Eric A., Findling, Robert L., and Horwitz, Sarah McCue

Subjects
LATENT variables, PREDICTION models, SUPERVISED learning, PSYCHOMETRICS
Abstract

Despite its potentials benefits, using prediction targets generated based on latent variable (LV) modeling is not a common practice in supervised learning, a dominating framework for developing prediction models. In supervised learning, it is typically assumed that the outcome to be predicted is clear and readily available, and therefore validating outcomes before predicting them is a foreign concept and an unnecessary step. The usual goal of LV modeling is inference, and therefore using it in supervised learning and in the prediction context requires a major conceptual shift. This study lays out methodological adjustments and conceptual shifts necessary for integrating LV modeling into supervised learning. It is shown that such integration is possible by combining the traditions of LV modeling, psychometrics, and supervised learning. In this interdisciplinary learning framework, generating practical outcomes using LV modeling and systematically validating them based on clinical validators are the two main strategies. In the example using the data from the Longitudinal Assessment of Manic Symptoms (LAMS) Study, a large pool of candidate outcomes is generated by flexible LV modeling. It is demonstrated that this exploratory situation can be used as an opportunity to tailor desirable prediction targets taking advantage of contemporary science and clinical insights. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Lurasidone for the Treatment of Irritability Associated with Autistic Disorder

Author

Loebel, Antony, Brams, Matthew, Goldman, Robert S., Silva, Robert, Hernandez, David, Deng, Ling, Mankoski, Raymond, and Findling, Robert L.

Abstract

The aim of this study was to evaluate the short-term efficacy and safety of lurasidone in treating irritability associated with autistic disorder. In this multicenter trial, outpatients age 6-17 years who met DSM-IV-TR criteria for autistic disorder, and who demonstrated irritability, agitation, and/or self-injurious behaviors were randomized to 6 weeks of double-blind treatment with lurasidone 20 mg/day (N = 50), 60 mg/day (N = 49), or placebo (N = 51). Efficacy measures included the Aberrant Behavior Checklist Irritability subscale (ABC-I, the primary endpoint) and the Clinical Global Impressions, Improvement (CGI-I) scale, and were analyzed using a likelihood-based mixed model for repeated measures. Least squares (LS) mean (standard error [SE]) improvement from baseline to Week 6 in the ABC-I was not significantly different for lurasidone 20 mg/day (-8.8 [1.5]) and lurasidone 60 mg/day (-9.4 [1.4]) versus placebo (-7.5 [1.5]; p = 0.55 and 0.36, respectively). CGI-I scores showed significantly greater LS mean [SE] improvement at Week 6 for lurasidone 20 mg/day versus placebo (2.8 [0.2] vs. 3.4 [0.2]; p = 0.035) but not for lurasidone 60 mg/day (3.1 [0.2]; p = 0.27). Discontinuation rates due to adverse events were: lurasidone 20 mg/day, 4.1%; 60 mg/day, 3.9%; and placebo, 8.2%. Adverse events with an incidence =10% (lurasidone combined, placebo) included vomiting (18.0, 4.1%) and somnolence (12.0, 4.1%). Modest changes were observed in weight and selected metabolic parameters. In this study, once-daily, fixed doses of 20 and 60 mg/day of lurasidone were not demonstrated to be efficacious compared to placebo for the short-term treatment of children and adolescents with moderate-to-severe irritability associated with autistic disorder.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results